<p>(a) Mark12™ Standard; (b) Purification step 1 elution pool; (c) Purification step 2 elution pool; (d) Purification step 3 elution pool; (e) Drug substance, HCP content: 30 ppm.</p
<p>(A) Denaturing gel analysis of the purified PAP fractions from Affigel Blue column by SDS-PAGE an...
<p>12% SDS-PAGE of proteins from the two purification steps. Lane 1, molecular weight markers; lane ...
<p>Panel A: Reducing SDS-PAGE, silver-stained. Panel B: Non-reducing SDS-PAGE, silver-stained. Panel...
<p>(a) Mark12™ Standard; (b) Reference material, drug substance level; (c) RP-HPLC fraction (24-26 m...
<p>(A) Lane 1, molecular weight markers (kDa); lane 2, liver extract; lane 3, diethylaminoethyl (DEA...
<p>Lane 1: protein standard; Lane 2: R18; Lane 3: R43. Powdered enzyme (100 µg) was dissolved in dis...
<p>A) Lane M, protein molecular weight markers; lane 1, uninduced cell sample; line 2, induced cell ...
<p>Lane 1–7 shows simulated digestion by gastric fluid and Lane 8–14 shows simulated digestion by in...
<p>Five samples with significant oxidase activity were selected, two from the control plate and thre...
<p>Batches with different HCP content at drug substance level (A) and the product elution pool after...
<p>SDS-PAGE analysis of extracts from all of the steps performed during purification of the full-len...
<p>Proteins (∼2 µg per lane) were reduced with 5% BME or loaded on a 12% gel in non-reducing conditi...
<p>Silver-staining. Lanes: (1) mAb04c, standard; (2) mother liquor with mAb04c and lysozyme; (3) was...
<p>Graphic presentation of the methodology of sample processing and LC-MS/MS analysis of pooled case...
<p><b>A.</b> Elution pattern of protease inhibitor on DEAE-Sepharose anion exchange column; <b>B</b>...
<p>(A) Denaturing gel analysis of the purified PAP fractions from Affigel Blue column by SDS-PAGE an...
<p>12% SDS-PAGE of proteins from the two purification steps. Lane 1, molecular weight markers; lane ...
<p>Panel A: Reducing SDS-PAGE, silver-stained. Panel B: Non-reducing SDS-PAGE, silver-stained. Panel...
<p>(a) Mark12™ Standard; (b) Reference material, drug substance level; (c) RP-HPLC fraction (24-26 m...
<p>(A) Lane 1, molecular weight markers (kDa); lane 2, liver extract; lane 3, diethylaminoethyl (DEA...
<p>Lane 1: protein standard; Lane 2: R18; Lane 3: R43. Powdered enzyme (100 µg) was dissolved in dis...
<p>A) Lane M, protein molecular weight markers; lane 1, uninduced cell sample; line 2, induced cell ...
<p>Lane 1–7 shows simulated digestion by gastric fluid and Lane 8–14 shows simulated digestion by in...
<p>Five samples with significant oxidase activity were selected, two from the control plate and thre...
<p>Batches with different HCP content at drug substance level (A) and the product elution pool after...
<p>SDS-PAGE analysis of extracts from all of the steps performed during purification of the full-len...
<p>Proteins (∼2 µg per lane) were reduced with 5% BME or loaded on a 12% gel in non-reducing conditi...
<p>Silver-staining. Lanes: (1) mAb04c, standard; (2) mother liquor with mAb04c and lysozyme; (3) was...
<p>Graphic presentation of the methodology of sample processing and LC-MS/MS analysis of pooled case...
<p><b>A.</b> Elution pattern of protease inhibitor on DEAE-Sepharose anion exchange column; <b>B</b>...
<p>(A) Denaturing gel analysis of the purified PAP fractions from Affigel Blue column by SDS-PAGE an...
<p>12% SDS-PAGE of proteins from the two purification steps. Lane 1, molecular weight markers; lane ...
<p>Panel A: Reducing SDS-PAGE, silver-stained. Panel B: Non-reducing SDS-PAGE, silver-stained. Panel...